GE HealthCare Technologies (GEHC) 51st Nasdaq London Investor Conference summary

Strategic direction and innovation

• Confirmed and improved midterm outlook with mid-single digit sales growth and margin expansion to high teens or above 20% over the next several years.

• Focused on innovation in pharmaceutical diagnostics, radiopharmaceuticals, and core imaging and ultrasound modalities.

• Emphasized security of supply in contrast media and innovation in radiopharmaceuticals, with new launches in Alzheimer's and cardiac imaging.

• Flyrcado, a next-generation PET imaging agent for myocardial perfusion, targets over $500 million in revenue by early 2028.

• Eight assets are under development in the pipeline, with strong interest in radio pharma and upcoming product launches.

Market environment and geographic trends

• U.S. hospital investment remains robust, with 8% sales growth and strong orders in the latest quarter.

• China market outlook remains uncertain due to macro, anti-corruption, and stimulus factors, with muted impact expected in the first half of next year.

• China has historically been volatile but remains a long-term growth catalyst.

Product and reimbursement developments

• Flyrcado received FDA approval, with first commercial shipments expected by end of Q1 next year.

• U.S. reimbursement changes will unbundle payments for PET diagnostics, improving hospital economics and encouraging adoption of advanced imaging agents.

• Anticipated migration from invasive, lower-cost diagnostics to higher-quality PET scans, especially in Alzheimer's care.